In a recent study, researchers measured the burden of antibiotic resistance in low- or middle-income countries, and reported that hospital mortality was significantly higher in patients with MDR or high resistance to XDR.
Researchers at the Center for Disease Dynamics, Economics and Policy analyzed microbiological sensitivity tests and mortality results for more than 4,000 patients who visited one of 10 hospitals for tertiary or quaternary referral across India in 2015. Pathogens were classified as MDR or XDR based on drug sensitivity profiles. Mortality figures were limited to death in hospitals.
The findings appear in the Journal of Clinical Infectious Diseases.
Other demographic and clinical data, including age, gender, location, infection, and hospital location (ie intensive care [ICU] Or intensive care unit).
The overall mortality rate among all participants was 13.1%, with a mortality rate of 29.0% among patients infected with A. baumanni. Patients who died were at greater risk of being older and admitted to the intensive care unit during the test. Researchers also found that among MDR infections, those caused by Gram negative bacteria were associated with higher mortality rates compared with those caused by gram positive bacteria, with rates of 17.7 percent and 10.8 percent, respectively.
The study found that patients who acquired MDR infections were 1.57 times more likely to be infected than those with similar sensitive infections, whereas patients who had acquired XDR infections were 2.65 times more likely to die when they thought of age, sex, and infection.
Both in the intensive care unit and in the intensive care unit, the mortality rate was higher in patients with XDR infection; This association was caused by Gram negative infections (eg, XDR K. pneumonia) that underlines the importance of rapid identification of these infections among all patients.
In India, MDR and XDR Gram negative bacteria are common infections, and the availability of effective antibiotic treatments are declining. This study provides greater insight into the urgent need to increase surveillance, research, and antimicrobial efforts worldwide. These findings on the mortality burden of antibiotic resistance can help develop policy efforts to prioritize antibiotic resistance as a global health threat and inform future efforts to quantify and track the burden of resistance across low and middle-level countries.